financetom
Business
financetom
/
Business
/
A.O. Smith forecasts annual profit below estimates on weak water heater demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
A.O. Smith forecasts annual profit below estimates on weak water heater demand
Jan 30, 2025 5:51 AM

Jan 30 (Reuters) - Water heater maker A. O. Smith ( AOS )

forecast full-year profit below estimates and also

missed fourth-quarter profit expectations on Thursday, hurt by

lower sales of its water heaters in North America and China.

A combination of job insecurity, a prolonged housing

downturn, debt and tariff threats from U.S. President Donald

Trump has weakened consumer demand in China, impacting the

company's sales.

"A. O. Smith's ( AOS ) 2024 sales declined due to a weak economy in

China continuing to negatively impact consumer demand and soft

North America water heater demand in the second half of the

year," said CEO Kevin J. Wheeler.

The company forecast 2025 adjusted profit between $3.60 and

$3.90 per share, missing analysts' estimates of $4.03 according

to data compiled by LSEG.

Shares of the company, which makes residential and

commercial water treatment products, were down 2.7% before the

bell.

Sales in the company's international segment fell above 4%

to $918.6 million in 2024, primarily due to weak demand in

China. The segment accounted for 25% of its total sales in 2023.

The Milwaukee, Wisconsin-based company has also been hit by

slow recovery in the residential housing market in the United

States.

A. O. Smith ( AOS ) reported adjusted earnings of 85 cents per share

for the quarter ended Dec. 31, down 12% from a year earlier.

Its overall revenue fell about 8% to $912.40 million for the

quarter, below analysts' average expectation of $953.93 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Telus to buy remaining digital unit stake for $539 million
Telus to buy remaining digital unit stake for $539 million
Sep 2, 2025
Sept 2 (Reuters) - Telus ( TU ) said on Tuesday it would buy the remaining shares in its digital services unit in a $539 million cash-and-stock deal, as the Canadian telecom company looks to expand its artificial intelligence capabilities. The company has offered $4.50 per share to buy the Telus Digital shares it does not own and take the...
Sector Update: Consumer Stocks Mixed Premarket Tuesday
Sector Update: Consumer Stocks Mixed Premarket Tuesday
Sep 2, 2025
09:10 AM EDT, 09/02/2025 (MT Newswires) -- Consumer stocks were mixed premarket Tuesday, with the Consumer Staples Select Sector SPDR Fund ( XLP ) 0.2% higher and the Consumer Discretionary Select Sector SPDR Fund ( XLY ) down 1.3%. PepsiCo ( PEP ) is facing a major activist campaign by hedge fund Elliott Investment Management, which has built a $4...
Market Chatter: TSMC's Waiver for China Shipments of Chip Supplies Gets Revoked by US
Market Chatter: TSMC's Waiver for China Shipments of Chip Supplies Gets Revoked by US
Sep 2, 2025
09:07 AM EDT, 09/02/2025 (MT Newswires) -- Taiwan Semiconductor Manufacturing's ( TSM ) waiver to freely ship essential inputs to its main Chinese chipmaking facility has been pulled by the US, Bloomberg reported Tuesday, citing a company statement. The chipmaker didn't immediately reply to a request for comment from MT Newswires. Shares were down over 3% in recent premarket activity....
Agilent Says Colorectal Cancer Test Gets European IVDR Certification as Companion Diagnostic
Agilent Says Colorectal Cancer Test Gets European IVDR Certification as Companion Diagnostic
Sep 2, 2025
09:11 AM EDT, 09/02/2025 (MT Newswires) -- Agilent Technologies ( A ) said Tuesday its MMR IHC Panel pharmDX has received class C companion diagnostic certification under EU in vitro diagnostic regulation for colorectal cancer. The test, developed in collaboration with Bristol-Myers Squibb ( BMY ) , helps in identifying mismatch repair-deficient colorectal cancer patients eligible for treatment with Bristol-Myers...
Copyright 2023-2026 - www.financetom.com All Rights Reserved